In early November 2019, the U.S. Food and Drug Administration (FDA) updated a previous safety communication about the potential of biotin to significantly interfere with diagnostic tests. The update reiterates the warning
G2 Lab and Pathology Insider
Subscribe today for full access
to all of these articles.
From - Diagnostic Testing & Emerging Technologies
Early in the year DTET spoke to experts that predicted 2015 would be the year that liquid biopsy technology penetrates the clinical oncology market. These predictions did not disappoint. A near continuous stream of publications, conference presentations, and…